The new outcome data were furthermore consistent with our previously reported increased risk of failure of antiestrogen therapy in a subgroup of breast cancer patients with low levels of the Nuc-pYStat5 biomarker as detected by fluorescence immunohistochemistry using the PM2000/AQUA platform.17 The gene discussed is NUCB1; the disease is breast cancer.